ClinicalTrials.Veeva

Menu

Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients

K

Kangstem Biotech

Status

Enrolling

Conditions

Atopic Dermatitis

Treatments

Other: Not applicable(observational study)

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

A Multi-center, Open, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of FURESTEM-AD inj. in Patients with Moderate to Severe Chronic Atopic Dermatitis Who Participated in a Placebo Group in K0102 Clinical Trial: 2nd Extension Study of K0102

Enrollment

99 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subject who enrolled K0102 Clinical Trial(parent study) and be assigned to a placebo group
  2. Subjects who understand and voluntarily sign an informed consent form

Exclusion criteria

  1. Subjects with medical history or surgery/procedure history
  2. Subjects with diseases at the time of participation in this study (systemic infection, other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis symptom region)
  3. Pregnant, breast-feeding women or women who plan to become pregnant during six months after administering the clinical trial medication
  4. Subjects who participate in other clinical trial or participated in other clinical trial within 4 weeks
  5. In case follow-up is not possible to end of this study period
  6. Any other condition which the investigator judges would make patient unsuitable for study participation

Trial design

99 participants in 1 patient group

Atopic Dermatitis
Treatment:
Other: Not applicable(observational study)

Trial contacts and locations

1

Loading...

Central trial contact

Jeong-hyang Woo; Seulbi Lee

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems